Danaher has completed its $9.9 billion acquisition of Masimo Corporation, a specialist in pulse oximetry and patient monitoring solutions. Masimo will now operate as a standalone company within Danaher's Diagnostics segment, retaining its brand identity as a wholly owned subsidiary, and its common stock has been delisted from the NASDAQ. Danaher views the deal as a strategic move to enhance its diagnostics portfolio in acute care settings through Masimo's sensor and AI-monitoring technologies, expecting it to accelerate Masimo's global reach. The company's current 2026 guidance remains unchanged for the second quarter, as Masimo is not expected to contribute materially until later in the year, with updated full-year 2026 financial guidance to be provided during the second-quarter earnings release.
Danaher CorporationDanaher completes $9.9B acquisition of Masimo, enhancing diagnostics portfolio in acute care.
Masimo CorporationMasimo acquired by Danaher at $9.9B, delisted; shareholders receive premium.